Helix BioPharma Corp.

Equities

HBP

CA4229101098

Biotechnology & Medical Research

Market Closed - Toronto S.E. Other stock markets 07:00:00 28/05/2024 pm IST			5-day change	1st Jan Change
0.205 ^CAD	0.00%		-2.38%	-2.38%

14/05	Helix BioPharma Corp. Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2024	CI
08/04	Helix BioPharma Corp. announced that it has received CAD 1.915 million in funding	CI

Helix BioPharma Corp. Announces Demise of S Slawomir Majewski, Interim Chief Executive Officer

March 16, 2022 at 05:43 pm IST

Helix BioPharma Corp. announced demise of its interim chief executive officer and chairman of the board of directors Prof. Dr. S Slawomir Majewski. Dr. Majewski has been on the board since 2012 and has led the company as its interim chief executive since September 2021.

Latest news about Helix BioPharma Corp.

Helix BioPharma Corp. Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2024	14/05	CI
Helix BioPharma Corp. announced that it has received CAD 1.915 million in funding	08/04	CI
Helix BioPharma Corp. announced that it expects to receive CAD 1.915 million in funding	28/03	CI
North American Morning Briefing : Markets Steady -2-	26/03	DJ
Helix BioPharma Corp. Appoints Praveen Varshney as Corporate Secretary	14/02	CI
Helix BioPharma Corp. Appoints Praveen Varshney as Chief Financial Officer	14/02	CI
North American Morning Briefing : S&P 500 Eyes Record High as Rate Cut Hopes Underpin Sentiment	19/12	DJ
Helix BioPharma Corp. Reports Earnings Results for the First Quarter Ended October 31, 2023	15/12	CI
North American Morning Briefing : Traders Eye -2-	12/12	DJ
Helix BioPharma Corp. Reports Earnings Results for the Full Year Ended July 31, 2023	28/23/28	CI
Helix BioPharma Corp. announced that it has received CAD 2.998 million in funding	27/23/27	CI
Helix BioPharma Corp. to Present New Preclinical Data on L-DOS47 in Combination with PD1 Checkpoint Inhibitor at the 2023 AACR- NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics	11/23/11	CI
Helix Biopharma Corp. Announces Board Changes	22/23/22	CI
Helix BioPharma Corp. Announces Executive Changes	22/23/22	CI
Helix BioPharma Corp. announced that it expects to receive CAD 2.998 million in funding	15/23/15	CI
Helix BioPharma Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended April 30, 2023	15/23/15	CI
North American Morning Briefing : Futures Rise -2-	21/22/21	DJ
Helix BioPharma Corp. Reports Earnings Results for the First Quarter Ended October 31, 2022	15/22/15	CI
North American Morning Briefing : Investors Wary -2-	14/22/14	DJ
Helix BioPharma Corp. Announces Board Changes	09/22/09	CI
Helix BioPharma Corp. Announces CEO Changes	09/22/09	CI
Helix BioPharma Corp. Reports Earnings Results for the Full Year Ended July 31, 2022	01/22/01	CI
Helix BioPharma Corp. announced that it has received CAD 4.62902 million in funding	31/22/31	CI
Helix BioPharma Corp. Auditor Raises 'Going Concern' Doubt	31/22/31	CI
Helix BioPharma Corp. Appoints Frank Gary Renshaw as Chief Medical Officer	04/22/04	CI

Chart Helix BioPharma Corp.

Duration

Period

More charts

Company Profile

Helix BioPharma Corp. is a Canada-based clinical-stage biopharmaceutical company. The Company is engaged in developing therapies in the field of immuno-oncology, based on its proprietary technological platform DOS47. DOS47 is an oncology platform technology that offers a debilitation and destruction of cancer cells. DOS47 is designed to stimulate an increase in the Potential of Hydrogen (pH) of the microenvironment surrounding the cancerous cells, effectively reversing the acidic extra cellular conditions that are believed to act to defend the tumor. L-DOS47 is an antibody protein conjugate where the urease component enzymatically converts naturally occurring urea to ammonia. The L-DOS47 drug molecule includes a specialized camelid-derived single domain antibody and is under clinical study for the treatment of non-small cell lung cancer and pancreatic cancer. V-DOS47 targets the vascular endothelial growth factor two receptor (VEGFR2).

Sector

Biotechnology & Medical Research

Calendar

25/10/2024 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
HELIX BIOPHARMA CORP.	-2.38%	3.45Cr
MODERNA, INC.	+54.05%	6.39TCr
IQVIA HOLDINGS INC.	-2.02%	4.18TCr
LONZA GROUP AG	+40.01%	4.05TCr
CELLTRION, INC.	-10.22%	2.72TCr
ICON PUBLIC LIMITED COMPANY	+13.42%	2.65TCr
ALNYLAM PHARMACEUTICALS, INC.	-21.60%	1.87TCr
BIO-TECHNE CORPORATION	+2.89%	1.27TCr
UNITED THERAPEUTICS CORPORATION	+22.40%	1.21TCr
MEDPACE HOLDINGS, INC.	+27.49%	1.21TCr

Other Biotechnology & Medical Research